Posters

Objective: A pooled analysis evaluated reductions in migraine and headache days among chronic migraine (CM) patients with comorbid depression (scores ≥10 on the 9-item Patient Health Questionnaire [PHQ-9]) in two placebo-controlled phase 3 trials of fremanezumab, a fully humanized monoclonal…

Background: Treatment-resistant depression (TRD) is a relatively common occurrence in clinical practice, with up to 50% to 60% of patients not achieving adequate response following antidepressant treatment. Repetitive Transcranial Magnetic Stimulation (rTMS) treatment for Major Depressive Disorder…

BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe pharmacotherapeutic augmentation options for individual patients. This clinical challenge may be particularly…

Background: Pharmacogenomic (PGx) testing is a potential tool to inform clinicians’ treatment decisions for patients with Major Depressive Disorder (MDD). However, there is mixed evidence available for the utility of PGx testing depending on the test used and population studied. Given the…

Individuals with severe mental illness are at increased risk for weight gain due to side effects from atypical antipsychotics and mood stabilizers, sedentary lifestyle, and social isolation. Obesity is a known risk factor for developing depression and their bidirectional relationship warrants…

Background: Repetitive transcranial magnetic stimulation (rTMS) is a method of noninvasively modulating focal brain activity and may be an effective treatment for Treatment Resistant Depression (TRD). Psychostimulants are frequently prescribed off-label for adults with major depressive disorder or…

Introduction: Study 303 (SUNRISE-2; NCT02952820) evaluated lemborexant (LEM) efficacy in subjects with insomnia. This post-hoc analysis examined sleep outcomes in the subgroup of subjects with a depression history vs subjects without a depression history (all other subjects). 

Background: Brexanolone injection (BRX) and the investigational compound, zuranolone (SAGE-217; ZRN), two neuroactive steroid (NAS) GABAA receptor positive allosteric modulators, were evaluated in four PPD randomized-controlled trials (RCTs). Both NASs achieved their primary endpoints (BRX:Hour 60…

Objective: This study determined differences in outcomes among respondents with and without a depression diagnosis and across symptom severity in respondents with diagnosed depression.

Background: Zuranolone (SAGE-217) is an investigational, neuroactive steroid and GABAA receptor positive allosteric modulator evaluated in a Phase 3 trial in patients with PPD (NCT02978326). Zuranolone achieved the primary endpoint of a statistically significant reduction in depressive symptoms…